Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

CONCLUSIONS: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.PMID:38592381 | DOI:10.1158/1078-0432.CCR-23-3639

Source: Clinical Cancer Research - April 9, 2024 Category: Cancer & Oncology Authors: Sangini S Sheth Ji Eun Oh Stefania Bellone Eric R Siegel Michelle Greenman Levent Mutlu Blair McNamara Shefali Pathy Mitchell Clark Masoud Azodi Gary Altwerger Vaagn Andikyan Gloria Huang Elena Ratner Daniel J Kim Akiko Iwasaki Angelique W Levi Natalia Bu Source Type: research